| Multiple Sclerosis - Drug Pipeline Analysis and | | | | restraints and challenges. Each trend is |
| Market Forecasts to 2015 | | | | independently researched to provide qualitative |
| | | | | analysis of its implications. |
| The report is an essential source of information | | | | - Key topics covered include strategic |
| and analysis on the global multiple sclerosis (MS) | | | | competitor assessment, market characterization, |
| market. The report identifies the key trends | | | | unmet needs and implications for future market |
| shaping and driving the global MS market. The | | | | associated with multiple sclerosis. |
| report also provides insight on the prevalent | | | | |
| competitive landscape and the emerging players | | | | Reasons to buy |
| expected to cause significant shifts in the market | | | | |
| positioning of the existing market leaders. Most | | | | The report will enhance your decision making |
| importantly, the report provides valuable insight on | | | | capability in a more rapid and time sensitive |
| the pipeline products within the global MS sector. ( | | | | manner. It will allow you to: |
| ) | | | | - Develop and design your in-licensing and |
| | | | | out-licensing strategies through review of pipeline |
| Scope | | | | products and technologies and by identifying |
| | | | | companies with the most robust pipeline. |
| The scope of the report includes: | | | | - Develop business strategies by understanding |
| - Annualized global multiple sclerosis market | | | | the trends shaping and driving the global multiple |
| revenues data from 2000 to 2008, forecast | | | | sclerosis market. |
| forward for 7 years to 2015. | | | | - Drive revenues by understanding key trends, |
| - Geographies covered in this report include the | | | | innovative products and technologies, market |
| US, the UK, Italy, Spain, Germany, France, and | | | | segments and companies likely to impact the |
| Japan. | | | | global multiple sclerosis market in future. |
| - Pipeline analysis data providing a split across | | | | - Formulate effective sales and marketing |
| different phases, mechanism of action being | | | | strategies by understanding the competitive |
| developed and emerging trends. Key classes of | | | | landscape and by analyzing the performance of |
| mechanism of action include immunomodulator and | | | | various competitors. |
| anti-inflammatory, cytokine and cytokine-receptor | | | | - Identify emerging players with potentially |
| targetters, ion channel targetters, metabolic | | | | strong product portfolio and create effective |
| pathway''s enzymes targetters, remyelination | | | | counter-strategies to gain competitive advantage. |
| stimulator and demyelination inhibitor, and | | | | - Organize your sales and marketing efforts by |
| neurotransmitters targetters. | | | | identifying the market categories and segments |
| - Analysis of the current and future market | | | | that present maximum opportunities for |
| competition in the global multiple sclerosis market. | | | | consolidations, investments and strategic |
| Key market players covered are Biogen idec, | | | | partnerships. |
| Merck Serono, Sanofi Aventis, AstraZeneca and | | | | - What’s the next big thing in the global |
| Glenmark Pharmaceuticals Ltd. | | | | multiple sclerosis market landscape? – Identify, |
| - Insightful review of the key industry drivers, | | | | understand and capitalize. |